Cognetivity Neurosciences Ltd
CNSX:CGN
Cognetivity Neurosciences Ltd
Research & Development
Cognetivity Neurosciences Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Cognetivity Neurosciences Ltd
CNSX:CGN
|
Research & Development
-CA$601.2k
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
Titan Medical Inc
TSX:TMD
|
Research & Development
$14k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Oncolytics Biotech Inc
TSX:ONC
|
Research & Development
-CA$18.2m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-5%
|
|
|
Avicanna Inc
TSX:AVCN
|
Research & Development
-CA$205.7k
|
CAGR 3-Years
16%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
C
|
Cannabix Technologies Inc
CNSX:BLO
|
Research & Development
-CA$2.6m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-24%
|
|
|
Microbix Biosystems Inc
TSX:MBX
|
Research & Development
-CA$2.3m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-7%
|
|
Cognetivity Neurosciences Ltd
Glance View
Cognetivity Neurosciences Ltd. operates as a technology company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-03-19. The firm is engaged in developing a cognitive testing platform, the integrated cognitive assessment (ICA), for use in medical and commercial environments for allowing early diagnosis of dementia. The Company’s ICA uses artificial intelligence and machine learning techniques to detect the earliest signs of cognitive impairment by testing the performance of brain. Its products include CognICA and OptiMind. The CognICA has various applications from early detection of cognitive impairment in dementia and multiple sclerosis (MS), to long-term health monitoring, corporate wellness, and personalized brain health. The OptiMind is a wellness app that measures individuals everyday cognitive performance. The firm serves various industries, including healthcare, elder care, enterprise, everyday use, and research. The ICA is available for clinical use in the United States of America, United Kingdom and Europe.
See Also
What is Cognetivity Neurosciences Ltd's Research & Development?
Research & Development
-601.2k
CAD
Based on the financial report for Jan 31, 2023, Cognetivity Neurosciences Ltd's Research & Development amounts to -601.2k CAD.
What is Cognetivity Neurosciences Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-49%
Over the last year, the Research & Development growth was -22%. The average annual Research & Development growth rates for Cognetivity Neurosciences Ltd have been -7% over the past three years , -49% over the past five years .
